TWI342313B - Vinyl alcohol-vinyl hydroxyl benzoate copolymer and composite film comprising the same - Google Patents
Vinyl alcohol-vinyl hydroxyl benzoate copolymer and composite film comprising the same Download PDFInfo
- Publication number
- TWI342313B TWI342313B TW094123147A TW94123147A TWI342313B TW I342313 B TWI342313 B TW I342313B TW 094123147 A TW094123147 A TW 094123147A TW 94123147 A TW94123147 A TW 94123147A TW I342313 B TWI342313 B TW I342313B
- Authority
- TW
- Taiwan
- Prior art keywords
- copolymer
- film
- composite film
- vinyl
- polymer
- Prior art date
Links
- 229920001577 copolymer Polymers 0.000 title claims description 23
- 239000002131 composite material Substances 0.000 title claims description 16
- 229920002554 vinyl polymer Polymers 0.000 title claims description 14
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 title claims description 12
- 241000191967 Staphylococcus aureus Species 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 241000222122 Candida albicans Species 0.000 claims description 6
- 229940095731 candida albicans Drugs 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229920001567 vinyl ester resin Polymers 0.000 claims description 4
- 108010025899 gelatin film Proteins 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 238000007334 copolymerization reaction Methods 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 20
- 238000012360 testing method Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N Vilsmeier-Haack reagent Natural products CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 230000000844 anti-bacterial effect Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000005886 esterification reaction Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 239000005711 Benzoic acid Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- -1 poly(vinyl salicylic acids) Polymers 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000000022 bacteriostatic agent Substances 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 125000002843 carboxylic acid group Chemical group 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- LODHFNUFVRVKTH-ZHACJKMWSA-N 2-hydroxy-n'-[(e)-3-phenylprop-2-enoyl]benzohydrazide Chemical compound OC1=CC=CC=C1C(=O)NNC(=O)\C=C\C1=CC=CC=C1 LODHFNUFVRVKTH-ZHACJKMWSA-N 0.000 description 2
- 239000005997 Calcium carbide Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- CLZWAWBPWVRRGI-UHFFFAOYSA-N tert-butyl 2-[2-[2-[2-[bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]-5-bromophenoxy]ethoxy]-4-methyl-n-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]anilino]acetate Chemical compound CC1=CC=C(N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)C(OCCOC=2C(=CC=C(Br)C=2)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)=C1 CLZWAWBPWVRRGI-UHFFFAOYSA-N 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Natural products C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical class OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical group OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- TXKMVPPZCYKFAC-UHFFFAOYSA-N disulfur monoxide Inorganic materials O=S=S TXKMVPPZCYKFAC-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940089491 hydroxycitric acid Drugs 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- QXSAKPUBHTZHKW-UHFFFAOYSA-N para-hydroxybenzamide Natural products NC(=O)C1=CC=C(O)C=C1 QXSAKPUBHTZHKW-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
1342313 、 九、發明說明: 【發明所屬之技術領域】 本發明係有關於一種共聚合物,特別是有關於一種乙烯醇-羥基苯曱酸乙烯酯共聚合物及包括該共聚合物之複合薄膜。 【先前技術】 將具生物活性的官能基以聚合方式形成連續重複單元的聚 合物,或以其他反應方式連接於聚合物主鏈上,形成不同以往 使用型式之材料設計或增強效用,儼然已發展成一專門之技術 ® 領域。其中具抗菌活性之聚合物的發展已在相關文獻上被陸續 發表出來,其可依活性發揮方式分成三大系統,一為聚合物主 體具有殺菌活性者,此類代表例有聚陽離子化合物(如含雙胍化 合物(biguanide)懸吊基之聚合物)或聚乙烯水楊酸(poly(vinyl salicylic acids))等。 二為利用聚合物當基質(matrix)使具活性之官能基在適當 時機分解釋放,例如塞普沙辛-聚己酸内酯(ciprofloxacin-polycarprolactone)縮合聚合物或聚乙烯醇-(胜肽連結子)-紫菌素 鲁 (PVA-(peptide linker)-gentamicin)共聚合物等。三為將抑菌劑經 材料技術導入高分子基質中使其達成控制釋放的作用,這類例 子相當多,有以尼龍(nylon)作為紗布材料者、以聚苯乙烯 (polystyrene)做基質者或以異丙醇基甲基纖維素 (2-hydroxypropyl methylcellulose)配合發泡設計使抗生素長期 滞留於胃部的藥劑等。 欲將具有抗菌活性的官能基鍵結入長鏈分子使其成為整體 具活性之共聚合物,經基苯甲酸(hydroxybenzoic acid)是極佳的 候選者。例如丙基對位經基苯甲酯(propyl /7-hydroxybenzoate 0806-A20988TWF(N2);david 5 1342313 (propyl paraben))對大部份菌屬有抑制能力,而上述衍生物酯化 鍵結均發生在對位羥基苯甲酸的羧酸基上,如此才能使其具有 活性甚或增強。 另 Albertsson等人在使用類似結構的2-經基笨甲酸 (2-hydroxy benzoic acid)即水楊酸(salicyclic acid)的經基與聚丙 稀酸(polyacrylicacid)進行酯化接合,以形成懸吊官能基之共聚 合物後發現抗菌活性喪失。當同時保留2-羥基苯甲酸的羥基及 羧酸基而在第四位碳上與乙烯(ethylene)鍵結再聚合形成聚合物 時則活性甚至大於原來之單體分子。經由對位羥基苯曱酸酯類 的形成和2-羥基笨曱酸與聚合鏈(聚丙烯酸或聚乙烯)接合的方 式的比較,相信將對位羥基笨曱酸上的羥基保留住並使其顯露 在分子外側時應具有一定的抗菌活性。至於與羧酸基形成酯化 之高分子主鏈上的重複單體結構若維持在4碳數内則應有修飾 其抗菌活性的效果,加上Dumitriu等人曾以醋化鍵結方式將萘 利啶酸(nalidixic acid)和PVA形成共聚合物的成功例子,故聚乙 烯醇(poly(vinyl alcohol), PVA)應為高分子主鏈的適當選擇。 【發明内容】 有鑑於此,本發明係提供一種乙烯醇-羥基苯甲酸乙烯酯共 聚合物,具有下列化學式(I): (CH2CH)m(CH2CH)n1342313, IX, invention: [Technical Field] The present invention relates to a copolymer, in particular to a vinyl alcohol-hydroxybenzoic acid vinyl ester copolymer and a composite film comprising the same . [Prior Art] The bioactive functional group is polymerized to form a continuous repeating unit polymer, or is connected to the polymer main chain by other reaction means to form a material design or enhance utility of different conventional use patterns, and has been developed. Into a specialized technology® field. The development of polymers with antibacterial activity has been published in related literatures. It can be divided into three major systems according to the way of activity. One is the bactericidal activity of the polymer body. Such representative examples are polycationic compounds (such as A polymer containing a biguanide suspension base or poly(vinyl salicylic acids) or the like. The second is to use the polymer as a matrix to decompose and release the active functional group at an appropriate timing, such as ciprofloxacin-polycarprolactone condensation polymer or polyvinyl alcohol-(peptide link) Sub)-PVA-(peptide linker)-gentamicin copolymer. The third is to introduce the bacteriostatic agent into the polymer matrix through material technology to achieve controlled release. There are quite a few examples of this type, such as nylon (nylon) as the gauze material, polystyrene (polystyrene) as the matrix or A drug designed to bind an antibiotic to the stomach for a long period of time with a 2-hydroxypropyl methylcellulose in combination with a foaming design. It is an excellent candidate for hydroxybenzoic acid to bond a functional group having antibacterial activity into a long-chain molecule to make it a wholly active copolymer. For example, propyl para-methyl benzyl benzoate ( propyl / 7-hydroxybenzoate 0806-A20988TWF (N2); david 5 1342313 (propyl paraben)) has an inhibitory ability against most of the genus, and the esterification bonds of the above derivatives are It occurs on the carboxylic acid group of para-hydroxybenzoic acid in order to make it active or even enhanced. In addition, Albertsson et al. used a similar structure of 2-hydroxy benzoic acid, a salicylic acid, to esterify with a polyacrylic acid to form a pendant functional group. The antibiotic activity was found to be lost after the base polymer. When the hydroxyl group and the carboxylic acid group of 2-hydroxybenzoic acid are simultaneously retained and repolymerized with ethylene at the fourth carbon to form a polymer, the activity is even larger than that of the original monomer molecule. By comparing the formation of para-hydroxybenzoic acid esters and the manner in which 2-hydroxy alum acid is bonded to a polymeric chain (polyacrylic acid or polyethylene), it is believed that the hydroxyl groups on the para-hydroxy alum acid are retained and allowed to It should have certain antibacterial activity when exposed to the outside of the molecule. As for the repeating monomer structure on the main chain of the esterified with a carboxylic acid group, if it is maintained at 4 carbon numbers, the antibacterial activity should be modified, and Dumitriu et al. have used naphthalene bonding to form naphthalene. A successful example of the formation of a copolymer of nalidixic acid and PVA, so polyvinyl alcohol (PVA) should be a suitable choice for the polymer backbone. SUMMARY OF THE INVENTION In view of the above, the present invention provides a vinyl alcohol-hydroxybenzoate copolymer having the following chemical formula (I): (CH2CH)m(CH2CH)n
OH (I) 0806-A20988TWF(N2) :david 6 1342313 其中m為42〜99,以及η為1〜57。 本發明另提供一種複合薄膜,包括一凝膠薄膜,該凝膠薄 膜包含上述之乙烯醇-羥基苯曱酸乙烯酯共聚合物。 【實施方式】 本發明係提供一種乙烯醇-羥基苯甲酸乙烯酯共聚合物,具 有化學式(I):OH (I) 0806-A20988TWF (N2): david 6 1342313 wherein m is 42 to 99, and η is 1 to 57. The present invention further provides a composite film comprising a gel film comprising the above-described vinyl alcohol-hydroxybenzoic acid vinyl ester copolymer. [Embodiment] The present invention provides a vinyl alcohol-hydroxybenzoate copolymer having the chemical formula (I):
在化學式(I)中,m可為42〜99,η可為1〜57。 化學式(I)可由下述方式合成,首先,混合羥基苯甲酸與溶 劑置於反應瓶中。羥基苯曱酸可包括鄰位、間位或對位取代之 羥基笨曱酸,或是含二個以上羥基取代之羥基笨曱酸,而溶劑 可為 Ν-甲基-2-氮伍圜酮(N-methyl-2-pyrrolidone, ΝΜΡ)、Ν,Ν_ 二甲基甲醯胺(Ν,Ν-dimethylformamide,DMF)、四氫呋味 (tetrahydrofuran,THF)或丙嗣(acetone)。接著,在室溫下,緩慢 加入活化劑以活化經基苯甲酸之缓基基團。活化劑可包括二氣 化亞硫醯(thionyl chloride) '三氣化填或五氣化鱗。待除去未反 應之活化劑後,即得到氣化羥基苯甲醯。 接著,混合聚乙烯醇與溶劑置於反應瓶中並加熱反應。所 使用之溶劑可包括N-曱基-2-氣伍圜酮(N-methyl-2-pyrrolidone, NMP)、N,N-二甲基甲酿胺(N,N-dimethylformamide,DMF)、四 0806-A20988TWF(N2);david 7 1342313 氫呋喃(tetrahydrofuran,THF)或丙酮(acetone)。待冷卻後,緩慢 加入上述之氣化羥基苯甲醯反應液,並在不同反應溫度(例如室 溫、攝氏65度及攝氏100度)下進行酯化反應,反應後,即可 獲得到本發明不同接枝率(酯化率)之乙烯醇-羥基苯甲酸乙烯酯 共聚合物。 本發明於不同反應溫度下進行酯化反應所得的產物其乙烯 醇與羥基笨曱酸鹽之接枝率大體介於40〜99%。 本發明之共聚合物可作為一抗菌劑,其對金黃色葡萄球菌 (•Siap/ijv/ococcws 之最低抑菌濃度(Minimum BacterialIn the formula (I), m may be 42 to 99, and η may be 1 to 57. The chemical formula (I) can be synthesized in the following manner. First, a mixed hydroxybenzoic acid and a solvent are placed in a reaction flask. The hydroxybenzoic acid may include an ortho, meta or para-substituted hydroxy citric acid or a hydroxy-cracked acid containing two or more hydroxy groups, and the solvent may be Ν-methyl-2-nitroglyoxime. (N-methyl-2-pyrrolidone, ΝΜΡ), Ν, Ν dimethyl dimethylformamide (DMF), tetrahydrofuran (THF) or acetone. Next, an activator is slowly added at room temperature to activate the base group of the benzoic acid. The activator may comprise a gasified thionyl chloride 'three gasified fill or five gasified scales. After the unreacted activator is removed, vaporized hydroxybenzimid is obtained. Next, the mixed polyvinyl alcohol and the solvent were placed in a reaction flask and the reaction was heated. The solvent used may include N-methyl-2-pyrrolidone (NMP), N,N-dimethylformamide (DMF), and four. 0806-A20988TWF (N2); david 7 1342313 Hydrofurfuran (THF) or acetone (acetone). After cooling, the above-mentioned gasified hydroxybenzimid reaction solution is slowly added, and esterification reaction is carried out at different reaction temperatures (for example, room temperature, 65 degrees Celsius and 100 degrees Celsius), and the reaction can be obtained. Vinyl alcohol-hydroxybenzoate copolymers of different graft ratios (esterification rates). The grafting reaction of the product obtained by the esterification reaction at different reaction temperatures of the present invention has a graft ratio of vinyl alcohol to hydroxy quesinate of from about 40 to 99%. The copolymer of the present invention can be used as an antibacterial agent against Staphylococcus aureus (• Minimum inhibitory concentration of Siap/ijv/ococcws (Minimum Bacterial)
Inhibition Concentration, MIC)大體介於 0.05 〜0.25%,對白色念 珠菌之最低抑菌濃度則介於0.5-1.0%。此 外,該共聚合物亦可作為一導電高分子。 本發明另提供一種複合薄膜,包括一凝膠薄膜,其包含上 述之乙烯醇-羥基苯甲酸乙烯酯共聚合物。 接著,說明本發明複合薄膜的製作,首先,混合乙烯醇-羥基苯甲酸乙烯酯共聚合物溶液與一凝膠聚合物。此共聚合物 溶液另包括例如為N-甲基-2-氮伍園酮(N-methyl-2-pyrrolidone, NMP)、N,N-二曱基甲醯胺(Ν,Ν-dimethylformamide,DMF)、四 氫呋峰(tetrahydrofuran,THF)或丙酮(acetone)的溶劑’而該凝膠 聚合物可為一矽凝膠聚合物。兩者均勻混合並乾燥後,除去殘 留溶劑,即可獲得此一複合薄膜。 以下藉由數個實施例以更進一步說明本發明之特徵和優 點。 【實施例】 實施例1 0806-A20988TWF(N2);david 8 1342313 乙烯醇-對位羥基苯甲酸乙烯酯共聚合物的合成 (CH2CH)m(CH2(j:Inhibition Concentration (MIC) is generally between 0.05 and 0.25%, and the minimum inhibitory concentration against Candida albicans is between 0.5 and 1.0%. Further, the copolymer may also function as a conductive polymer. The present invention further provides a composite film comprising a gel film comprising the above-described vinyl alcohol-hydroxybenzoate copolymer. Next, the production of the composite film of the present invention will be described. First, a vinyl alcohol-hydroxybenzoate copolymer solution and a gel polymer are mixed. The copolymer solution further includes, for example, N-methyl-2-pyrrolidone (NMP), N,N-dimercaptocarbamide (Ν, Ν-dimethylformamide, DMF). ), a solvent of tetrahydrofuran (THF) or acetone, and the gel polymer may be a monolithic gel polymer. After the two are uniformly mixed and dried, the residual solvent is removed to obtain the composite film. The features and advantages of the present invention are further illustrated by the following examples. EXAMPLES Example 1 0806-A20988TWF(N2); david 8 1342313 Synthesis of vinyl alcohol-para-hydroxybenzoic acid copolymer (CH2CH)m (CH2(j:
H)n OH Ο I c=oH)n OH Ο I c=o
OH 合成步驟: (1)氣化對位羥基笨曱醯的合成OH synthesis step: (1) Synthesis of vaporized para-hydroxy alum
首先,混合10克的對位羥基笨甲酸(相當於〇〇724 m〇le) 與40毫升的N-甲基-2-氮伍圜酮(NMP)置於圓形平底玻璃瓶 中,攪拌使之溶解。同時,組裝一迴流裝置,並於冷凝管接口 處加裝一含無水氣化鈣之玻璃接引管,以除去空氣令之水氣。 接著’於㈣過程中徐徐加人4.8毫升的二氣化亞硫酿(相當於 0.0657 mo丨e)’㈣位經基苯甲酸與二氣化亞硫酿的反應莫耳比 為1 . 0.9於至皿下持續反應!小時。反應後,卸除迴流裝置, 將反應瓶轉置於減壓乾燥箱中,以壓力15厘米水銀柱(C 及溫度40C的條件下加熱24小時,以除去未反應的二氣化亞 硫酿及二氧化硫’此時應注意保持操作環境的乾燥。 0806-A20988TWF(N2) :david 1342313 (2)乙烯醇-對位羥基苯曱酸乙烯酯共聚合物的合成First, mix 10 g of para-hydroxy benzoic acid (equivalent to 〇〇 724 m〇le) with 40 ml of N-methyl-2-nitrosudolone (NMP) in a round flat-bottomed glass bottle and stir. Dissolved. At the same time, a reflow device is assembled, and a glass outlet tube containing anhydrous calcium carbide is added to the interface of the condenser to remove air and moisture. Then, in the process of (4), 4.8 ml of di-sulfurized sulphur (equivalent to 0.0657 mo丨e) was added. The reaction molar ratio of benzoic acid to di-sulfurized sulphur was 1. 0.9. Continue to react under the dish! hour. After the reaction, the reflux device was removed, and the reaction flask was transferred to a vacuum drying oven and heated under a pressure of 15 cm of a mercury column (C and a temperature of 40 C for 24 hours to remove unreacted gasified sulfurized sulfur and sulfur dioxide. 'At this time, care should be taken to keep the operating environment dry. 0806-A20988TWF(N2) :david 1342313 (2) Synthesis of vinyl alcohol-para-hydroxybenzoic acid vinyl ester copolymer
(CHsCHLi^CH^ Ο OH c=o(CHsCHLi^CH^ Ο OH c=o
OHOH
混合適當量的聚乙烯醇與nmp置於圓形平底玻璃瓶中,於 油浴鍋中加熱至約120°C使之完全溶解並取出冷卻。同時,組 裝一迴流裝置並在冷凝管接口處加裝一含無水氣化鈣之玻璃接 引管,以除去空氣中之水氣。於攪拌過程中徐徐加入含有二倍 乙烯醇單體莫耳數的氣化對位羥基苯甲醯反應液,分別以三種 反應溫度(包括室溫、65°C及100。〇進行酯化反應,最後獲得本 發明之乙烯醇-對位羥基笨甲酸乙烯酯共聚合物。而各反應溫度 所得到的平均酯化率分別為41.6%(室溫)、97.4±2.2%(65。0)以及 97.3 土〇.6%(1〇〇。〇。 在合成乙稀醇-對位羥基苯曱酸共聚合物的過程中,溫度顯 然是提高醋化率的關鍵因素,同時亦影響酯化反應達飽和時之 時間’若加熱溫度不足,即使經過長時間反應,最終的酯化率 亦相對偏低。因此’提高溫度應可使反應物有足夠能量超越活 化複體的能量障礙而有助反應進行,例如提高溫度可克服形成 0806-A20988TWF(N2);david 10 1342313 接枝侧鏈時所產生的分子排斥。若溫度繼續提高至100〇c,最後 純化檢品其質地會相對地堅硬,不過經水解率分析知其酯化率 仍可高達97.3%士0.6%。 實施例2 最低抑菌濃度(MIC)測定 此處所稱的MIC係指每毫升含2 X 1〇4個菌體(ceus)的培養 液中,最終完全抑制菌落生長所需抑菌成分的最低濃度。MIC 的測疋首先需作三種菌種之單株培養,即先取附著大腸桿菌 ATCC10536)冷凍菌株的玻璃珠2個,加約4 毫升滅菌的胰蛋白大豆瓊脂培養基(TSB),旋搖使附著菌胞溶出 成旋濁液,以1ML容量的移菌圈沾取懸濁液,劃線於營養瓊脂 培養基(nutrient agar)圓盤培養皿上,以37°C怪溫倒置培養24 小時,使劃線之近末端處得單一菌落,以移菌圈挑取該單一菌 落放入盛有10毫升營養液體培養基(nutrient br〇th)的試管中, 混合均勻後37 C再次培養約20小時,所得試管中菌液濃度為 108士 1004cells/mL (1σ,測定次數n=3),再以滅菌蒸餾水稀釋成 濃度106cells/mL後用於抗菌試驗。 再取附著金黃色葡萄球菌⑽似⑽〜似 ATCC6538P)冷凍菌株的玻璃珠2個,同前大腸桿菌操作方式, 但用滅菌蒸餾水代替胰蛋白大豆瓊脂培養基(TSB),所得試管中 菌液濃度為108土10O7cells/mL(la,n=3),再以滅菌蒸餾水稀釋成 濃度H)6CellS/mL。最後取附著白色念珠菌(c⑽心心似 ATCC10231)冷;東菌株的玻璃珠4個,加約4毫升滅菌蒸館水, 旋搖使附著菌胞溶散成旋濁液,以丨容量之移菌圈沾取懸濁 0806-A20988TWF(N2):david 1342313 液’劃線於酵母菌與黴菌培養基(YM agar)圓盤培養皿上,以 25 C恆溫倒置培養48小時,使劃線之近末端處得單一菌落,以 移菌圈挑取該單一菌落,放入盛有1〇毫升營養液體培養基之試 管中混合均勻後於25°C再次培養48小時,所得試管中菌液濃 度為 106±l〇0-2cells/mL (1σ,n=3)。 完成菌種培養後,開始進行MIC測定,首先,將對位經基 苯曱酸、酯化聚合物(試驗組)分別配製成一系列濃度的檢液,包 括1.0%、0.5%、0.25%及0.05%。由於醋化聚合物難溶於水,故 1.0%酯化聚合物的配製是先以丙二醇加熱溶解後再以水稀釋, 此時丙二醇之濃度為10%(ν/ν)·>另配製空白組以對應不同濃度 檢液中的溶劑組成,包括了 10%、5%、2.5%、0.5% (v/v)的丙二 醇水溶液。之後,使用微量移液管分次取〇·丨毫升、濃度1〇6 cells/mL·的三種菌液,並分別加入4.9毫升上述各種濃度的酯 化聚合物檢液、對位羥基苯甲酸檢液及空白液混合均勻。接著, 以25 C怪溫培養24小時進行抑菌反應試驗,以1 〇μ[容量的移 菌圈沾取試驗液,在培養皿上劃線,此處大腸桿菌和金黃色葡 萄球菌之培養皿用營養瓊脂作為培養基,白色念珠菌則使用酵 母菌與黴菌培養基(YM agar)。每支試管重複做3個培養基的劃 線’大腸桿菌和金黃色葡萄球菌試驗組之培養姐於3 7。c倒置培 養24小時,白色念珠菌試驗組則於25。(:倒置培養48小時,最 後取出培養血觀察菌落生長情形。 MIC的判定是藉由菌落計數器放大鏡觀察生成的菌落來進 行,並裁定個別抑菌劑對單一菌種重覆培養的三個培養基均無 菌落生長時所需最低抑菌劑濃度即為MIC。此處以室溫醋化的 0806-A20988TWF(N2);david 12 1342313 共聚合物進行試驗,最後得到共聚合物對金黃色葡萄球菌、大 腸桿菌、白色念珠菌的跳分別為㈣5%、G 25%、Q 5% (w/v), 而對位每基苯甲酸對上述菌種之MIC則分別為。挪、〇帆、 1.0% (Wv)”x本試驗結果觀察自旨化聚合物的MIC似乎比單分 子的對位經基苯曱酸對金黃色葡萄球菌與白色料菌有較 抑菌效果。 實施例3 複合薄膜的製作 首先,製作一凝膠材料,步驟如下,混合5毫升的四氧乙 烯石夕院(tetraethoxysilane^ 2〇毫升、95%的乙醇置於刚毫升 燒杯中,並以磁性㈣器㈣,過財徐徐加人H)毫升、_ N的鹽酸,室溫下,再持續㈣2G小時,即可得到—凝膠咖㈣ 態的矽膠網狀聚合物β 與上述石夕溶膠混合以製成薄膜的各種溶液分別為·⑴混合 i克的聚乙稀醇與1()毫升的Ν,Ν_:甲基甲酿胺於欧油浴中 加熱使其軟化、分散’之後,加水溶解,最後再以水稀釋至 毫升。(2)配製含有〇」克對位經基苯甲酸與iq毫升Ν,Ν-二甲基 甲酿胺的溶液。(3)混合克的共聚合物產物與h毫升的Ν,Ν_ 二甲基甲醯胺& 13G°C油浴中加熱溶解以配製成-共聚合物備 儲溶液。 接下來製作二種複合薄膜,第一種含5%(w/w)的醋化聚 合物’第二種含5%(w/w)的對位經基苯子酸,第三種則不含任 何抑菌劑成/7 t作步驟是將前述之溶液適量加人碎凝膠(si^a yogel)中均勾合,然後將混合液平鋪於硬質製成的小盒 中,再以 120 C 及 ^ Α g的負壓乾燥16小時,以除去殘留溶 0806-A20988TWF(N2) ;david 1342313 劑尤其疋⑸弗點的N’N_二甲基甲醯胺,即可形成乾燥的複合薄 膜,以扁平藥构取下,並以Waltmam Mass. AMES 214-25厚声 測定儀量測其平均厚度。 又 實施例4 複合薄膜之抗菌效益評估 複合薄膜的抗菌試驗係將前述濃度1〇6ceUs/mL的大腸桿 菌3、金f色,萄球菌標準菌液以營養液體培養基稀釋成濃度 • 10、10、10 cells/mL的稀釋液,並各移取兩份1毫升的稀釋 液至約含15毫升營養壞脂培養基的培養皿t (直徑90 mm),旋 搖使其平均分佈於培養基表面上。待凝固後將15 χ 1 5咖2大小 _的各種薄膜以無菌録子平放於含菌表面上,共得兩組培養皿, -組為大腸桿菌,另—組為金黃色㈣球菌,每組各含有三個 不同菌數(103、1〇4、1〇5菌體)的培養皿每個培養血在等距位 置處平貼上f#膜。最後,將貼好薄膜的培養皿置人价的 箱中倒置培養24小時。 —本發明複合薄膜的抗菌效益評估是以革蘭氏染色方式進 鲁 使用本法的原因在於薄膜上任何存活的細菌細胞若經類 似前述單株培養方式的移菌培養,會生長出更多菌落,在判斷 抑菌效果上易生困擾,而革蘭氏染色可將試驗檢品染色的程度 與控制組(即未含抑菌劑的薄膜)及比較組(即含5 %對位經基苯 甲酸的薄膜)做明顯對照,以利抑菌效果判斷。 以無菌錄子取下經培養的薄膜,裁剪後將薄膜的細菌接觸 面朝上並平放於載玻片上,滴1至2滴滅菌蒸館水於薄膜上浸 潤2至3分鐘,然後快速通過火焰以固定薄膜,接著,滴數滴 紫色草酸鹽結晶水溶液(〇xa]ate crystal vi〇】et s—)將薄膜完 0806-A20988TWF(N2) ;david 1342313 全覆蓋’靜置1分鐘後,加滅菌蒸餾水洗淨薄膜,然後滴數滴 優碘溶液(lugol-PVP Iodine complex solution)於薄膜上使其完全 次潰溶液中,靜置1分鐘後,加滅菌蒸餾水洗淨薄膜。續用 的乙醇-丙酮混合液(50:50, v/v)脫色至無任何色素再溶出然後 再滴入數滴番紅溶液(safranin s〇luti〇n)並使其完全覆蓋薄膜。進 行1分鐘著色後用滅菌蒸餾水洗淨,風乾後用顯微鏡放大至6〇〇 倍觀察染色情形,並以電荷偶合裝置數位相機攝影記錄影像。 矽凝膠複合薄膜的抗菌效益是透過革蘭氏染色法進行評 估如革蘭氏陽性菌金黃色葡萄球菌(兄存在時,薄膜應 呈藍色,革藺氏陰性菌如大腸桿菌(£ 存在時,薄膜則應呈 紅色。結果顯示在植入丨〇3金黃色葡萄球菌菌落數於培養姐上的 這組,含5%在室溫合成的共聚合物的薄膜呈些微陰性反應(薄 膜呈紅色)’即顯示細菌無法有效生長。 當抗菌劑與與其他高分子共同形成複合薄膜後,基本上活 性官能基受限於高分子結構組成的槽穴中,其活動的有效空間 減少,亦即自由容積(free volume)縮小,為減少這樣的限制及能 適當地評估一般溶劑難溶的高酯化率聚合物所能發揮的抗 用,本發明選擇具有多孔洞性f及對許多微生物具有親合性的 矽凝膠作為薄膜基質。 雖然本發明已以較佳實施例揭露如上,然其並非用以限定 本發明。任何熟習此技藝者,在不脫離本發明之精神和範圍内’ 备可作些許之更動與潤冑。因此本發明<保護範圍當視後附之 申請專利範圍。 0806-A20988TWF(N2);david 15 1342313 • · 【圖式簡單說明】 - 〇 4 *«、 【主要元件符號說明】 fe 〇 «»»>A suitable amount of polyvinyl alcohol and nmp were mixed in a round flat-bottomed glass bottle, heated in an oil bath to about 120 ° C to dissolve completely and taken out for cooling. At the same time, a reflow device is assembled and a glass tube containing anhydrous calcium carbide is added to the condenser port to remove moisture from the air. During the stirring process, the gasification para-hydroxybenzamide reaction solution containing the molar number of the vinyl alcohol monomer is slowly added, and the esterification reaction is carried out at three reaction temperatures (including room temperature, 65 ° C and 100 Torr, respectively). Finally, the vinyl alcohol-para-hydroxy hydroxybenzoate copolymer of the present invention was obtained, and the average esterification rates obtained at the respective reaction temperatures were 41.6% (room temperature), 97.4±2.2% (65. 0), and 97.3, respectively. Soil 〇.6% (1〇〇.〇. In the process of synthesizing the ethylene-para-hydroxybenzoic acid copolymer, the temperature is obviously a key factor for increasing the acetification rate, and also affects the esterification reaction to saturation. Time of time 'If the heating temperature is insufficient, even after a long period of reaction, the final esterification rate is relatively low. Therefore, 'increasing the temperature should allow the reactants to have enough energy to overcome the energy barrier of the activated complex and help the reaction proceed. For example, increasing the temperature can overcome the molecular repulsion generated when the graft side chain is formed by 0806-A20988TWF(N2); david 10 1342313. If the temperature continues to increase to 100 〇c, the final purified sample will be relatively hard, but hydrolyzed. Rate analysis The rate of conversion can still be as high as 97.3% ± 0.6%. Example 2 Minimum inhibitory concentration (MIC) determination The MIC referred to herein refers to the culture solution containing 2 X 1 4 cells (ceus) per ml, and finally complete The minimum concentration of bacteriostatic components required to inhibit colony growth. The MIC test first requires the cultivation of three strains of single strain, that is, the glass beads of the frozen strain attached to Escherichia coli ATCC10536 are first added, and about 4 ml of sterilized trypsin is added. Soy agar medium (TSB) was shaken to dissolve the adherent cells into a turbid liquid, and the suspension was taken up with a 1 ML-capacity transfer line and streaked onto a nutrient agar disc culture dish to 37 Incubate in °C for 24 hours, so that a single colony is obtained at the proximal end of the scribing line. Pick the single colony into the test tube containing 10 ml of nutrient br〇th and mix evenly. After 37 C was cultured for another 20 hours, the concentration of the bacterial solution in the obtained test tube was 108 ± 1004 cells/mL (1σ, the number of measurements n=3), and then diluted to a concentration of 106 cells/mL with sterile distilled water for the antibacterial test. Staphylococcus aureus (10) like (10) ~ ATCC6538P) Two glass beads of frozen strain, the same as the previous E. coli operation mode, but with sterile distilled water instead of tryptic soy agar medium (TSB), the concentration of the obtained liquid in the test tube was 108 soil 10O7cells/mL (la, n=3) And diluted with sterile distilled water to a concentration of H) 6 CellS / mL. Finally, the attached Candida albicans (c (10) heart like ATCC10231) cold; 4 strains of glass beads of the eastern strain, add about 4 ml of sterilized steaming water, spin to make the attached bacteria dissolve into a turbid liquid, to transfer the capacity of the bacteria Circle the suspension 0806-A20988TWF (N2): david 1342313 liquid 'striped on the yeast and mold medium (YM agar) disc culture dish, incubate at 25 C constant temperature for 48 hours, so that the end of the line A single colony was obtained, and the single colony was picked by a transfer fungus, mixed in a test tube containing 1 ml of nutrient liquid medium, and then cultured again at 25 ° C for 48 hours, and the concentration of the obtained liquid in the test tube was 106 ± l. 0-2 cells/mL (1σ, n=3). After the culture of the strain is completed, the MIC measurement is started. First, the para-benzoic acid and the esterified polymer (test group) are separately prepared into a series of concentrations of the test liquid, including 1.0%, 0.5%, and 0.25%. And 0.05%. Since the acetated polymer is hardly soluble in water, the 1.0% esterified polymer is prepared by heating with propylene glycol and then diluting with water. The concentration of propylene glycol is 10% (ν/ν)·> The group consists of solvents corresponding to different concentrations of the test solution, including 10%, 5%, 2.5%, 0.5% (v/v) aqueous propylene glycol solution. After that, three kinds of bacterial liquids of 〇·丨 ml and concentration of 1〇6 cells/mL· were collected by using a micropipette, and 4.9 ml of the above-mentioned various concentrations of the esterified polymer test liquid and the para-hydroxybenzoic acid test were respectively added. Mix the liquid and the blank separately. Next, incubated at 25 C for 24 hours to carry out a bacteriostatic reaction test, and take a test solution with 1 〇μ [capacity of the transfer zone, streak the dish, where the E. coli and S. aureus culture dish Nutrient agar was used as the medium, and Candida albicans used yeast and mold medium (YM agar). The lines of the three media were repeated for each tube. The culture of the E. coli and S. aureus test groups was 37. c was inverted for 24 hours, and the Candida albicans test group was at 25. (: Inverted culture for 48 hours, and finally the cultured blood was taken out to observe the colony growth. The MIC was judged by the colony observed by the colony counter magnifying glass, and the three culture media in which the individual bacteriostatic agents were repeatedly cultured on a single strain were determined. The minimum bacteriostatic concentration required for aseptic growth is the MIC. Here, the room temperature is varnished with 0806-A20988TWF (N2); david 12 1342313 copolymer, and finally the copolymer is obtained against Staphylococcus aureus and large intestine. The hops of Bacillus licheniformis and Candida albicans were (4) 5%, G 25%, and Q 5% (w/v), respectively, and the MIC of the para-basic benzoic acid to the above species was respectively: N., 〇, 1.0% ( Wv)”x The results of this test show that the MIC of the self-derived polymer seems to have a more bacteriostatic effect than the monomolecular para-benzoic acid against Staphylococcus aureus and white bacteria. Example 3 Production of composite film First , to make a gel material, the steps are as follows, mix 5 ml of tetraethoxysilane (2 cc, 95% ethanol in a fresh ML beaker, and magnetic (four) device (four), too rich and add people H) ML, _ N salt At room temperature, for another 4 hours, it can be obtained. The gelatin coffee network (four) state of the silicone network polymer β and the above-mentioned stone sol are mixed to form a film of various solutions respectively (1) mixed with i grams of polyethylene Alcohol with 1 () ml of hydrazine, Ν _: methyl methamine in the European oil bath to soften, disperse ', then add water to dissolve, and finally dilute to ML with water. (2) Preparation containing 〇 gram pair a solution of benzoic acid with iq ml hydrazine, hydrazine-dimethyl ketoamine. (3) mixed gram of copolymer product with h ml of hydrazine, hydrazine dimethyl dimethyl carbamide & 13G ° C oil The bath was heated and dissolved to prepare a -copolymer stock solution. Next, two composite films were prepared, the first containing 5% (w/w) of the acetated polymer 'the second containing 5% (w/ w) the para-position of phenylic acid, the third does not contain any bacteriostatic agent / 7 t as the step is to add the appropriate amount of the above solution to the human gel (si ^ a yogel), and then The mixture was plated in a hard-made small box and dried under a vacuum of 120 C and Α g for 16 hours to remove the residual solution 0806-A20988TWF (N2); david 1342313 agent especially 疋 (5) N'N-dimethylformamide at the point of the point can form a dry composite film, which is taken out in a flat form and measured for average thickness by a Waltmam Mass. AMES 214-25 Thick Sound Meter. Example 4 Antibacterial Benefit Evaluation of Composite Film The antibacterial test of the composite film was prepared by diluting the above-mentioned concentration of 1〇6ceUs/mL of Escherichia coli 3, gold f color, and Staphylococcus aureus standard solution in a nutrient liquid medium to a concentration of 10, 10, 10 cells. /mL of the dilution, and each of the two 1 ml of the dilution was transferred to a Petri dish t (90 mm in diameter) containing about 15 ml of nutrient bad fat medium, which was evenly distributed on the surface of the medium by shaking. After coagulation, the various films of 15 χ 1 5 coffee 2 size _ were placed on the bacteria-containing surface with a sterile recording, and two sets of culture dishes were obtained. The group was Escherichia coli, and the other group was golden yellow (four) cocci, each group. Each of the culture dishes containing three different bacterial numbers (103, 1〇4, 1〇5 cells) was flattened with an f# membrane at equidistant positions. Finally, the film-coated culture dish was placed in a box and inverted for 24 hours. - The antibacterial benefit evaluation of the composite film of the present invention is carried out by Gram staining. The reason for using this method is that any surviving bacterial cells on the film will grow more colonies if they are transplanted by a similar single culture method. It is easy to be troublesome in judging the antibacterial effect, and Gram stain can stain the test sample with the control group (ie, the film containing no bacteriostatic agent) and the comparison group (ie containing 5% para-base benzene). The formic acid film was used as a clear control to judge the antibacterial effect. Remove the cultured film with a sterile record. After cutting, place the bacterial contact side of the film face up and lay it on the slide. Drip 1 to 2 drops of sterilized steaming water onto the film for 2 to 3 minutes, then quickly pass The flame is fixed to the film, and then a few drops of purple oxalate crystal solution (〇xa]ate crystal vi〇] et s-) is finished with the film 0806-A20988TWF (N2); david 1342313 full coverage 'after standing for 1 minute, The film was washed with sterilized distilled water, and then a solution of a total amount of iodine solution (lugol-PVP Iodine complex solution) was applied to the film to completely collapse the solution. After standing for 1 minute, the film was washed with sterilized distilled water. The continuously used ethanol-acetone mixture (50:50, v/v) was decolorized to remove any pigment and then added dropwise to a few drops of safranin (safranin s〇luti〇n) and completely covered with the film. After being colored for 1 minute, it was washed with sterilized distilled water, air-dried, magnified by a microscope to 6 倍 times to observe the staining condition, and the image was recorded by a digital camera of a charge coupling device. The antibacterial benefit of the 矽 gel composite film is evaluated by Gram staining method such as Gram-positive bacteria Staphylococcus aureus (the film should be blue when the brother is present, and the Gram-negative bacteria such as Escherichia coli The film should be red. The results showed that in the group of 丨〇3 Staphylococcus aureus colonies implanted in the culture, the film containing 5% of the copolymer synthesized at room temperature showed a slight negative reaction (the film was red) "It shows that the bacteria can not grow effectively. When the antibacterial agent and the other polymers form a composite film, the active functional groups are basically limited to the cavity of the polymer structure, and the effective space for the activity is reduced, that is, free. The volume of the free volume is reduced, and in order to reduce such limitations and to properly evaluate the resistance of a high esterification rate polymer which is generally insoluble in a solvent, the present invention is selected to have a porous cavity and has affinity for many microorganisms. The bismuth gel is used as the film substrate. Although the invention has been disclosed above in the preferred embodiments, it is not intended to limit the invention. Anyone skilled in the art will not Within the spirit and scope of the present invention, there may be some modifications and simplifications. Therefore, the scope of the present invention is defined in the appended claims. 0806-A20988TWF(N2);david 15 1342313 • · [Simple diagram Description] - 〇4 *«, [Description of main component symbols] fe 〇«»»>
0806-A20988TWF(N2);david 160806-A20988TWF(N2);david 16
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW094123147A TWI342313B (en) | 2005-07-08 | 2005-07-08 | Vinyl alcohol-vinyl hydroxyl benzoate copolymer and composite film comprising the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW094123147A TWI342313B (en) | 2005-07-08 | 2005-07-08 | Vinyl alcohol-vinyl hydroxyl benzoate copolymer and composite film comprising the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200702343A TW200702343A (en) | 2007-01-16 |
| TWI342313B true TWI342313B (en) | 2011-05-21 |
Family
ID=45074827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094123147A TWI342313B (en) | 2005-07-08 | 2005-07-08 | Vinyl alcohol-vinyl hydroxyl benzoate copolymer and composite film comprising the same |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI342313B (en) |
-
2005
- 2005-07-08 TW TW094123147A patent/TWI342313B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200702343A (en) | 2007-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110804144B (en) | Cationic-zwitterionic block copolymers | |
| CN105797193B (en) | A kind of Thermo-sensitive arginine base long acting antibiotic aerogel dressing and preparation method thereof | |
| JP7475765B2 (en) | Antibacterial polymeric composition | |
| CN107286355B (en) | Cationic-zwitterionic copolymer and polycaprolactone blend film and preparation method and application thereof | |
| CN114989345A (en) | A kind of antibacterial and antioxidant hydrogel with self-healing function and preparation method thereof | |
| CN111138571B (en) | Polyvinylpyrrolidone-iodoform biomimetic complex polymer and preparation method thereof | |
| CN110669690A (en) | A Lactobacillus plantarum strain expressing quorum sensing signal molecule AI-2 and its application | |
| CN107652393A (en) | Adsorption antibacterial sugar-containing polymer and preparation method thereof | |
| KR102893078B1 (en) | Antibacterial polymer composition | |
| CN114560778B (en) | Gemini quaternary ammonium salt and its preparation method and application | |
| TWI342313B (en) | Vinyl alcohol-vinyl hydroxyl benzoate copolymer and composite film comprising the same | |
| CN118697933A (en) | Preparation method and use of self-healing medical hydrogel | |
| JPH06239941A (en) | Antimicrobial polymer | |
| CN112480435B (en) | Injectable antibacterial hydrogel material and preparation method thereof | |
| CN114432506A (en) | Zwitterion functionalized biological material, and preparation method and application thereof | |
| TWI763558B (en) | Anti-biofouling material, blood-contacting medical device containing the same and manufacturing method of the same | |
| JPH01308431A (en) | Silk fibroin hydrogel | |
| CN118459668A (en) | A polyionic liquid modified bacterial cellulose-based packaging film material and its preparation method and application | |
| CN110627955A (en) | Zwitterionization-based polyvinylimidazole terpolymer and preparation method and application | |
| CN116003463A (en) | Monoguanidine functional graphene oxide bactericide and preparation method and application thereof | |
| CN102133409B (en) | Sterilizing type medical ultrasonic coupling agent and preparation method thereof | |
| CN119505074B (en) | A kind of temperature sensitive gel and preparation method thereof | |
| CN107011473A (en) | Leucine methacrylate homopolymer, preparation method and application in antibacterial | |
| CN120098289B (en) | Antibacterial hydrogel with wet surface adhesion | |
| RU1837059C (en) | Method for producing solid nutrient medium for cultivation of microorganism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |